Top

Published in:

01-11-2010 | Melanomas

Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma

Authors: Ali Cadili, MD, MSc, Richard A. Scolyer, MD, FRCPA, FRCPath, Philip T. Brown, MD, FRCPA, Kelly Dabbs, MD, MSc, FRCSC, John F. Thompson, MD, FRACS, FACS

Published in: Annals of Surgical Oncology | Issue 11/2010

Abstract

Introduction

In patients with a primary melanoma ≥1.0mm in Breslow thickness, the rate of metastasis to regional lymph nodes, as determined by sentinel node biopsy (SLNB), is approximately 20%. Among the patients with a positive SLNB result, however, only approximately 20% have tumor identified in additional non-SLNs. Therefore, many melanoma patients are still subjected to the morbidity of a complete lymph node dissection (CLND) without obvious benefit. In the current study, we analyzed the clinical and pathologic features of melanoma patients with positive SLNBs treated at the Melanoma Institute Australia. The aim was to correlate clinical and pathologic features of both the primary melanoma and the SLN metastases, including total SLN metastasis, with non-SN metastasis and (disease specific and overall) survival.

Methods

Total SLN tumor size was obtained by adding the largest diameters of all individual metastatic deposits within the SLN. Clinicopathological variables analyzed included patient age at the time of diagnosis, primary tumor characteristics (histologic type, Breslow thickness, ulceration, mitotic rate, site of primary tumor), and SLNB characteristics (date of SLNB procedure, location of LN field, number of draining LN fields, number of SLNs harvested, number of positive SLNs, size of largest metastatic deposit, total metastatic deposit size, location of metastasis within the SLN, extra nodal extension (ENE), and number of metastatic deposits within the SLN). The correlation between each of the predictor variables and outcome was determined by univariate analysis. The predictor variables that correlated with NSLN metastasis with a p value < 0.10 on univariate analysis were then entered into a multivariate model.

Results

There were 606 patients with a positive SNSNB result who proceeded to a CLND. The median number of NSNs in CLND specimens was 18 and the median number of positive NSLNs was 2.68. Of the patients with SN metastasis, 23.5% also had NSLN metastasis on CLND. Total SLN tumor size was significantly correlated to NSLN metastasis, melanoma-specific survival and overall survival on both univariate and multivariate analyses.

Conclusion

Total SN tumor size predicts the likelihood of non-SLN metastasis, and also predicts survival outcome.

Thompson JF, McCarthy WH, Bosch CM, O’Brien CJ, Quinn MJ, Paramaesvaran S, Crotty K, McCarthy SW, Uren RF, Howman-Giles R. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995;5(4):255–60.CrossRefPubMed

Elias N, Tanabe KK, Sober AJ, et al. (2004) Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Arch Surg. 139:400–5.CrossRefPubMed

Reeves ME, Delgado R, Busam KJ, et al. (2003) Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 10:27–31.CrossRefPubMed

Wagner JD, Gordon MS, Chuang T-Y, et al. (2000) Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 89:453–62.CrossRefPubMed

Starz H, Balda BR, Krämer KU, Büchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91(11):2110–21.CrossRefPubMed

Scolyer RA, Li LX, McCarthy SW, Shaw HM, Stretch JR, Sharma R, Thompson JF. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol. 2004;122(4):532–9.CrossRefPubMed

Frankel TL, Griffith KA, Lowe L, Wong SL, Bichakjian CK, Chang AE, Cimmino VM, Bradford CR, Rees RS, Johnson TM, Sabel MS. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol. 2008;15(9):2403–11.CrossRefPubMed

Cadili A, Smylie M, Danyluk J, Dabbs K. Prediction of nonsentinel lymph node metastasis in malignant melanoma. J Surg Res. 2009;154(2):324–9.CrossRefPubMed

Scolyer RA, Li LX, McCarthy SW, Shaw HM, Stretch JR, Sharma R, Thompson JF. Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. Melanoma Res. 2004;14(4):263–8.CrossRefPubMed

10.

Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15(4):1202–10.CrossRefPubMed

11.

Satzger I, Volker B, Meier A, et al. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol. 2008;15(6):1723–32.CrossRefPubMed

12.

Debarbieux S, Duru G, Dalle S, et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol. 2007;157(1):58–67.CrossRefPubMed

13.

Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201(1):37–47.CrossRefPubMed

14.

Page AJ, Carlson GW, Delman KA, et al. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg. 2007;73(7):674–8; discussion 678–9.

15.

McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2002;9(2):137–41.CrossRefPubMed

16.

Morton DL. Sentinel node mapping and an International Sentinel Node Society: current issues and future directions. Ann Surg Oncol. 2004;11(3 Suppl):137S–43S.PubMed

17.

Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34.PubMed

18.

Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.CrossRefPubMed

Title: Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma
Authors: Ali Cadili, MD, MSc
Richard A. Scolyer, MD, FRCPA, FRCPath
Philip T. Brown, MD, FRCPA
Kelly Dabbs, MD, MSc, FRCSC
John F. Thompson, MD, FRACS, FACS
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 11/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1145-6

At a glance: The STEP trials

Springer Medicine

Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2010

Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases

Role of MMP-3 and MMP-9 and Their Haplotypes in Risk of Bladder Cancer in North Indian Cohort

Disparities in Utilization of High-Volume Hospitals for Cancer Surgery: Results of a Korean Population-Based Study

Mucinous Gastric Cancer Presents with More Advanced Tumor Stage and Weaker β-Catenin Expression than Nonmucinous Cancer

Prospective Evaluation of the Rate and Impact of Hemolysis on Intraoperative Parathyroid Hormone (IOPTH) Assay Results

Sentinel Lymph Node Intraoperative Imprint Cytology in Patients with Breast Cancer—Costly or Cost Effective?